Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL.

Global epidemiology of HTLV-I infection and associated diseases.

Oncogene 2005; 24:6058-6068.

2. Farid R, Etemadi M, Baradaran H, Nikbin B. Seroepidemiology

and virology of HTLV-I in the city of Mashhad, northeastern Iran.

Serodiag Immun Inf D 1993; 5:251-252.

3. Abbaszadegan MR, Gholamin M, Tabatabaee A, Farid R, Houshmand

M, Abbaszadegan M. Prevalence of human T-lymphotropic

virus type 1 among blood donors from Mashhad, Iran. J Clin Microbiol

2003; 41:2593-2595.

4. Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR,

Guedes AC,

et al.

Epidemiology, treatment, and prevention of human

T-cell leukemia virus type 1-associated diseases. Clin Micro

277

Dermatologic Manifestation in HTLV-I Carriers Yazdanpanah MJ R et al

Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013

biol Rev 2010; 23:577-589.

5. Blattner W, Charurat M. Human T-cell lymphotropic virus type

1 and 2. In: Principle and practice of infectious disease. (Mandell

G, Bennet JE, Dolin R, ed). 6th ed. Philadelphia: Elsevier;

2005.p.2098-2118.

6. Goncalves DU, Guedes AC, Proietti AB, Martins ML, Proietti FA,

Lambertucci JR. Interdisciplinary HTLV-I/II Research Group: Dermatologic

lesions in asymptomatic blood donors seropositive

for human T cell lymphotropic virus type-I. Am J Trop Med Hyg

2003; 68:562-565.

7. Nobre V, Guedes AC, Proietti FA,

et al

. Increased prevalence of

human T cell lymphotropic virus type 1 in patients attending a

Brazilian dermatology clinic. Intervirology 2007; 50:316-318.

8. Nobre V, Guedes AC, Martins ML, Barbosa-Stancioli EF, Serufo JC,

Proietti FA,

et al

. Dermatological findings in 3 generations of a

family with a high prevalence of human T cell lymphotropic virus

type 1 infection in Brazil. Clin Infect Dis 2006; 43:1257-1263.

9. Watanabe A, Kawajiri M, Ikezoe K, Osoegawa M, Murai H, Ochi H

,

et al

. HTLV-I-associated myelopathy/tropical spastic paraparesis

accompanied with psoriasis. J Neurol Sci 2004; 221:95-97.

10. Guillevin L, Cohen P. Polyarteritis nodosa: clinical, prognostic

and therapeutic features. Ann Med Int 2000; 151:184-192.

11. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical

and immunological findings in seventy-eight patients and a

review of the literature. J Infect 2005; 50:375-381.

12. Amano M, Setoyama M, Grant A, Kerdel FA. Human T-lymphotropic

virus 1 (HTLV-I) infection--dermatological implications.

Int J Dermatol 2011; 50:915-920.

13. Arfi S, Durget D, Vernant JCI, Numeric P, De Thore J, Jean-Baptiste

G.Dermatopolymyositis in Martinique. Relations with the virus.

Rev Med Int 1992; 13:S452.

14. Bataille V, Harland CC, Behrens J, Cook MG, Holden CA. Kikuchi

disease (histiocytic necrotizing lymphadenitis) in association

with HTLV-I. Br J Dermatol 1997; 136:610-612.

15. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective

dermatitis of Jamaican children: a marker for HTLV-I infection.

Lancet 1990; 336:1345-1347.

16. Oliveira Mde F, Brites C, Ferraz N, Magalhaes P, Almeida F, Bittencourt

AL. Infective dermatitis associated with the human T cell

lymphotropic virus type I in Salvador, Bahia, Brazil. Clin Infect

Dis 2005; 40:e90-96.

17. Maragno L, Casseb J, Fukumori LM, Sotto MN, Duarte AJ, Festa-

Neto C,

et al

. Human T-cell lymphotropic virus type 1 infective

dermatitis emerging in adulthood. Int J Dermatol 2009; 8:723-

730.

18. Sanchez-Palacios C, Gotuzzo E, Vandamme AM, Maldonado Y.

Seroprevalence and risk factors for human T-cell lymphotropic

virus (HTLV-I) infection among ethnically and geographically diverse

Peruvian women. Int J Infect Dis 2003; 7:132-137.

19. Soares BC, Proietti AB, Proietti FA. Interdisciplinary HTLV-I/II

Research Group. HTLV-I/II and blood donors: determinants associated

with seropositivity in a low risk population. Rev Saude

Publica 2003; 37:470-476.

20. Lewkowicz N, Lewkowicz P, Banasik M, Kurnatowska A, Tchorzewski

H. Predominance of Type 1 cytokines and decreased number

of CD4 (+) CD25 (+high) T regulatory cells in peripheral blood of

patients with recurrent aphthous ulcerations. Immunol Lett

2005; 99:57-62.

21. Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS,

John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced

stages of primary cutaneous T-cell lymphoma. J Invest

Dermatol 2006; 126:2217-2223.

22. Karube K, Ohshima K, Tsuchiya T,

et al

. Expression of FoxP3, a key

molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/

lymphoma cells. Br J Haematol 2004; 126:81-84.

23. Yamano Y, Takenouchi N, Li HC,

et al

. Virus-induced dysfunction

of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological

disease. J Clin Invest 2005; 115:1361-1368.

24. Kuroda Y, Takashima H. Impairment of cell-mediated immune

responses in HTLV-I-associated myelopathy. J Neurol Sci 1990;

100:211-216.

25. Remondegui C, Bueno J, Pintado A. AIDS Research and Human

Retroviruses: A case of strongyloidosis hyperinfection in a

HTLV-I carrier. 10th International Conference on Human Retro

virology: HTLV and Related Viruses. 2001 June 25-29;Dublin

Ireland:2001.p.142.

26. Ajithkumar K, Ramalingam S, Kannangai R, Prakash KJ. Human T

lymphotrophic virus-I (HTLV-I) infection in patients with unclassifiable

dermatitis in central Kerala, south India: a preliminary

study. Sex Transm Infect 2002; 78:E7.

27. Nobre V, Guedes AC, Proietti FA,

et al

. Dermatologic lesions in patients

infected with the human T-cell lymphotropic virus type 1

(HTLV-I). Rev Soc Bras Med Trop 2005; 38:43-52.

28. Del Giudice P. Scabies in HTLV-I seropositive patients. J Am Acad

Dermatol 1997; 36:134-135.

29. Javidi Z, Farid R, Taheri AR,

et al

. A study of HTLV-I seroposetivity

in vitiligo. Med J Mashhad Univ Med Sci 2004; 82:114-119.(Persian)

30. Sharata HH, Colvin JH, Fujiwara K, Goldman B, Hashimoto K. Cutaneous

and neurologic disease associated with HTLV-I infection.

J Am Acad Dermatol 1997; 36:869-871.

31. Primo J, Siqueira I, Nascimento MC, Oliveira MF, Farre L, Carvalho

EM,

et al.

High HTLV-I proviral load, a marker for HTLV-I associated

myelopathy/tropical spastic paraparesis, is also detected in

patients with infective dermatitis associated with HTLV-I. Braz J

Med Biol Res 2009; 42:761-764.

32. Nascimento MC, Primo J, Bittencourt A, Siqueira I, de Fatima

Oliveira M, Meyer R, Schriefer A, Santos SB, Carvalho EM. Infective

dermatitis has similar immunological features to human T lymphotropic

virus-type 1-associated myelopathy/tropical spastic